HIV/AIDS Drug Receives Tentative Approval

February 2011
Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p11
The article reports on the tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS relief (PEPFAR) of drugs for AIDS treatment including Lamivudine and Zidovudine tablets.


Related Articles

  • Underground AIDS drugs and the FDA: An uneasy truce.  // Patient Care;8/15/1993, Vol. 27 Issue 13, p60 

    Reports on the acknowledgement of AIDS buyers' club for underground therapies by the Food and Drug Administration. Criteria for operation; Drugs for personal use and under a physician's care; Absence of promotions for products; Absence of unreasonable risks; Requirement of prescriptions;...

  • AIDS research: Out of the hospital.  // Patient Care;9/30/1993, Vol. 27 Issue 15, p23 

    Reports on the benefits to be derived from the employment of the community based trial model in gaining Food and drug Administration (FDA) approval for AIDS treatments and drugs. Delay in the conventional approval process; Limitations of community-based trials; Financial issues; Use on drug...

  • New class of AIDS drug may extend survival.  // Mayo Clinic Health Letter;Jun1996, Vol. 14 Issue 6, p4 

    Reports on the Food and Drug Administration's approval of two new AIDS medications called ritonavir and indinavir. Ritonavir and indinavir as part of a new class of drugs known as protease inhibitors; Effectiveness of the drugs in helping slow the progression of AIDS; Mayo Clinic infectious...

  • Battling AIDS fraud. J.H. // FDA Consumer;Mar1996, Vol. 30 Issue 2, p30 

    Reports on the Food & Drug Administration's (FDA) collaboration with several states to establish the AIDS Health Fraud Task Force Network, which aims to curb AIDS fraud through various information programs. Sponsorship of consumer education; Florida case involving a hand lotion the distributor...

  • FDA gives quick OK of AIDS drug but wants more answers.  // Nation's Health;Dec95, Vol. 25 Issue 11, p14 

    Reports that the US Food and Drug Administration (FDA) approved the use of 3TC in combination with AZT for the treatment of AIDS-related infections after less than five months of review. Drugs members of the nucleoside analogue class of compounds; Adverse reactions to the drugs.

  • Truth in advertising. Kirby, David // Advocate;06/05/2001, Issue 839, p15 

    Reports that the United States Food and Drug Administration (FDA) has send letters to drug companies to reform their advertisements for AIDS drugs. Factors that influence the FDA decision; Opposition against companies that sell their drugs in a competitive marketplace.

  • APPLICATIONS FOR ddI AND FOSCARNET DELAYED. Delaney, Martin // Advocate;10/22/91, Issue 588, p33 

    Reports that applications for approval of the AIDS-related drugs ddI and foscarnet have been held up for weeks because of unrelated congressional demands on the U.S. Food and Drug Administration. Representative Charles Dingell's request for volumes of data, files, and testimony regarding the...

  • Prodrugs of HIV Protease Inhibitors. Vierling, Pierre; Greiner, Jacques // Current Pharmaceutical Design;Aug2003, Vol. 9 Issue 22, p1755 

    Despite the efficiency of the present polytherapies against AIDS, HIV replication continues indicating difficulties in drug adherence, drug-drug interactions, resistance issues, and the existence of reservoirs or sanctuaries for the virus. Moreover, most of the current FDA-approved HIV protease...

  • FDA Changes AZT Dose Advice. Helquist, Michael // Advocate;2/27/90, Issue 545, p30 

    Reports on the decision of the U.S. Food and Drug Administration (FDA) to change its recommendation regarding the dosage of the anti-AIDS drug AZT. Pressure from health advocates to formalize research data indicating the effectiveness of half doses of AZT; Updated dose recommendation; Lessening...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics